FDA clears expansion of CeloNova ’s nano-coated coronary stent trial
CeloNova Biosciences said today that the FDA approved an expansion of the on-going clinical trial for its Cobra PzF nano-coated coronary stent with 14-day dual antiplatelet therapy in complex patients, like people who are at a high risk of bleeding.
The company touted its Cobra Reduce trial as the first randomized control trial to study 14-day DAPT following percutaneous coronary intervention.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA clears expansion of CeloNova’s nano-coated coronary stent trial appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Stents Vascular CeloNova BioSciences Source Type: news
More News: Angioplasty | Bleeding | Clinical Trials | Coronary Angioplasty | Nanotechnology | Percutaneous Coronary Intervention | Study